PortfoliosLab logoPortfoliosLab logo
CPRX vs. QQ.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CPRX vs. QQ.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and QinetiQ Group plc (QQ.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Different Trading Currencies

CPRX is traded in USD, while QQ.L is traded in GBp. To make them comparable, the QQ.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, CPRX achieves a 34.36% return, which is significantly higher than QQ.L's 7.41% return. Over the past 10 years, CPRX has outperformed QQ.L with an annualized return of 46.26%, while QQ.L has yielded a comparatively lower 9.23% annualized return.


CPRX

1D
-0.03%
1M
0.64%
YTD
34.36%
6M
32.77%
1Y
29.11%
3Y*
39.03%
5Y*
40.44%
10Y*
46.26%

QQ.L

1D
-2.10%
1M
14.75%
YTD
7.41%
6M
10.91%
1Y
-6.03%
3Y*
13.28%
5Y*
7.40%
10Y*
9.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CPRX vs. QQ.L - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CPRX
Catalyst Pharmaceuticals, Inc.
34.36%11.84%24.15%-9.62%174.74%102.69%-10.93%95.31%-50.90%272.38%
QQ.L
QinetiQ Group plc
7.41%16.51%34.93%-6.83%22.49%-15.85%-5.88%32.93%19.94%-1.29%

Correlation

The correlation between CPRX and QQ.L is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.06

Correlation (5Y)
Calculated over the trailing 5-year period

0.08

Correlation (10Y)
Calculated over the trailing 10-year period

0.08

Correlation (All Time)
Calculated using the full available price history since Jul 11, 2007

0.08

Fundamentals

Market Cap

CPRX:

$3.98B

QQ.L:

£2.47B

EPS

CPRX:

$1.74

QQ.L:

-£0.14

PS Ratio

CPRX:

6.68

QQ.L:

0.67

PB Ratio

CPRX:

3.93

QQ.L:

4.47

Total Revenue (TTM)

CPRX:

$596.96M

QQ.L:

£3.85B

Gross Profit (TTM)

CPRX:

$378.23M

QQ.L:

£372.10M

EBITDA (TTM)

CPRX:

$313.50M

QQ.L:

£533.20M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CPRX vs. QQ.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
CPRX Risk / Return Rank: 6969
Overall Rank
CPRX Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
CPRX Sortino Ratio Rank: 6666
Sortino Ratio Rank
CPRX Omega Ratio Rank: 6666
Omega Ratio Rank
CPRX Calmar Ratio Rank: 7171
Calmar Ratio Rank
CPRX Martin Ratio Rank: 7171
Martin Ratio Rank

QQ.L
QQ.L Risk / Return Rank: 3434
Overall Rank
QQ.L Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
QQ.L Sortino Ratio Rank: 3131
Sortino Ratio Rank
QQ.L Omega Ratio Rank: 3232
Omega Ratio Rank
QQ.L Calmar Ratio Rank: 3737
Calmar Ratio Rank
QQ.L Martin Ratio Rank: 3636
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. QQ.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and QinetiQ Group plc (QQ.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CPRXQQ.LDifference
Sharpe ratioReturn per unit of total volatility

+1.07

Sortino ratioReturn per unit of downside risk

+1.46

Omega ratioGain probability vs. loss probability

1.18

0.99

+0.19

Calmar ratioReturn relative to maximum drawdown

1.52

-0.22

+1.75

Martin ratioReturn relative to average drawdown

3.46

-0.46

+3.91

CPRX vs. QQ.L - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.89, which is higher than the QQ.L Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of CPRX and QQ.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CPRX vs. QQ.L - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, which is greater than QQ.L's maximum drawdown of -61.16%. Use the drawdown chart below to compare losses from any high point for CPRX and QQ.L.


Loading charts...

Drawdown Indicators


CPRXQQ.LDifference

Max Drawdown

Largest peak-to-trough decline

-94.25%

-61.16%

-33.09%

Max Drawdown (1Y)

Largest decline over 1 year

-19.18%

-27.17%

+7.99%

Max Drawdown (3Y)

Largest decline over 3 years

-27.29%

-32.62%

+5.33%

Max Drawdown (5Y)

Largest decline over 5 years

-45.37%

-33.81%

-11.56%

Max Drawdown (10Y)

Largest decline over 10 years

-64.87%

-43.00%

-21.87%

Current Drawdown

Current decline from peak

-0.03%

-16.76%

+16.73%

Average Drawdown

Average peak-to-trough decline

-51.96%

-20.64%

-31.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.84%

13.21%

-3.37%

Volatility

CPRX vs. QQ.L - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 0.47%, while QinetiQ Group plc (QQ.L) has a volatility of 11.53%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than QQ.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CPRXQQ.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.47%

11.53%

-11.06%

Volatility (6M)

Calculated over the trailing 6-month period

23.17%

23.14%

+0.03%

Volatility (1Y)

Calculated over the trailing 1-year period

33.28%

31.96%

+1.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.77%

32.45%

+15.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.39%

31.01%

+29.38%

Dividends

CPRX vs. QQ.L - Dividend Comparison

CPRX has not paid dividends to shareholders, while QQ.L's dividend yield for the trailing twelve months is around 1.91%.


PositionTTM20252024202320222021202020192018201720162015
CPRX
Catalyst Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
QQ.L
QinetiQ Group plc
1.91%2.00%1.99%2.49%2.04%2.59%2.06%1.84%2.20%2.60%2.17%1.99%

Financials

CPRX vs. QQ.L - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and QinetiQ Group plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M1.00B20222023202420252026
149.39M
1.02B
(CPRX) Total Revenue
(QQ.L) Total Revenue
Please note, different currencies. CPRX values in USD, QQ.L values in GBP

CPRX vs. QQ.L - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and QinetiQ Group plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
10.8%
Portfolio components
CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

QQ.L - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, QinetiQ Group plc reported a gross profit of 110.20M and revenue of 1.02B. Therefore, the gross margin over that period was 10.8%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

QQ.L - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, QinetiQ Group plc reported an operating income of 110.20M and revenue of 1.02B, resulting in an operating margin of 10.8%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

QQ.L - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, QinetiQ Group plc reported a net income of 69.20M and revenue of 1.02B, resulting in a net margin of 6.8%.


Frequently Asked Questions


CPRX and QQ.L have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for CPRX and QQ.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer